23andMe Unilateral Programs Sample Clauses

23andMe Unilateral Programs. If GSK declines to participate in further research and discovery activities with respect to an Identified Target following the Target Discovery Phase (such that it does not become a Collaboration Target), then 23andMe may elect to progress the Identified Target into a 23andMe Unilateral Program, which 23andMe may conduct at its sole discretion subject to the applicable terms and conditions of this Agreement. With respect to any 23andMe Unilateral Program, 23andMe may use its own biopharmaceutical capacity or 23andMe may request that GSK conduct discovery activities on the Target for new chemical entities to identify a developable candidate molecule on a fee-for-service basis (and on reasonable terms and conditions to be set forth in a separate written agreement between the Parties). However, GSK shall not be required to conduct such activities for more than one 23andMe Unilateral Program during the Term. Alternatively, for clarity, 23andMe is permitted, without GSK’s consent and at 23andMe’s discretion, to work on any 23andMe Unilateral Program with, or to grant rights to Develop, Manufacture and Commercialize Unilateral Products arising from such 23andMe Unilateral Program to, one or more Third Parties. 23andMe will pay a royalty on Net Sales of any products developed in a 23andMe Unilateral Program as per TABLE 1 of Section 10.7, subject to the terms and conditions of Article 10.